ValiRx Announces Promising In Vivo Results for its Lead Molecule VAL 101
News Jun 27, 2008
ValiRx plc, the cancer therapeutics and diagnostics company, has announced promising in vivo results for its lead molecule VAL 101 which uses its gene silencing technology GeneICE™ in preclinical xenograph models of pancreatic cancer.
Studies showed that the tumor growth was less than half the size of that seen in the control group.
Based on these results, the Company will now initiate further preclinical studies with the aim of progressing VAL 101 toward Phase I regulatory filing by initiating toxicology studies. The Company has also recently expanded its product portfolio with the development of a second GeneICE™ anti-cancer molecule.
ValiRx’s GeneICE™ technology platform utilizes the cells’ own inherent gene control machinery to effectively silence genes involved in cancer cell progression, in the case of VAL 101, targeting the anti-apoptotic gene BCL-2. These latest in vivo results follow on from studies earlier this year which provided evidence that GeneICE™ could trigger cell death in ovarian, pancreatic and prostate cancer cells.
The application of GeneICE™ technology in both studies targeted the BCL-2 gene, which is often over-expressed in certain types of cancer and may lead to the development of chemotherapeutic cell-death resistance.
The Company’s GeneICE™ technology platform recruits gene silencing factors known as Histone Deacetylase Complexes (HDACs) to genes involved in cancer cell progression, inhibiting their expression and activation. ValiRx is currently using the GeneICE™ platform to target other genes implicated in disease, including targets involved in neurological disease.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018